Blog

For many companies, signal detection in drug safety pharmacovigilance ranks closely behind regulatory submissions and case management as a key activity because it helps to proactively monitor a product’s risks that come to light from tracking the data submitted to internal and external drug safety databases and platforms.

“The most competitive pharma companies in the coming decade will be masters of data and digital technologies.” So begins the June 2017 industry brief, “Reinventing the Role of Medical Affairs,” by Bain & Company.

LifeSphere® Mobile MA is the first multi-lingual, self-service medical information portal and mobile app to help…

LifeSphere® Clinical is the industry’s first pre-validated, unified eClinical research platform for clinical operations and clinical data management. Along with…

From reporting challenges to data integration and data silos with clinical data management, to the continuing search for greater automation,…

LifeSphere® Safety MultiVigilance is the only E2B R3 compliant multi-tenant cloud solution in the safety market. Customers already…

As different regulatory authorities have different timelines for adoption of these standards, E2B(R2) E2B(R3) will have to coexist. But having to operate two solutions creates huge complexities, unless you find a solution compliant with both. ArisGlobal LifeSphere Safety MultiVigilance is the only drug safety database solution provider thus far to provide full compliance to E2B R2 and E2B R3 standards for both import and export.

Artificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world…

The clinical trial sector witnessed a lot of action in 2016. Pharmaceutical establishments are increasing their focus on this branch…

Silos have long plagued the life sciences industry, and nowhere is this more notable than with how information and data…